- 2025.2.5
- News Release Revolution in the field of eye diseases: biotech research collaboration between Naples and Tokyo to develop revolutionary therapies
- 2024.3.13
- News Release Prof. Yohei Yamauchi of ETH Zurich and TAGCyx Announces a Research Collaboration for the discovery of a novel Xenoligo® aptamer in the field of infectious diseases field.
- 2024.3.11
- News Release Shinji Oki, PhD, at National Center of Neurology and Psychiatry and TAGCyx Announces a research collaboration for the treatment for systemic lupus erythematosus using a novel nucleic acid aptamer.
- 2024.1.31
- News Release SBI Pharmaceuticals and TAGCyx ANNOUNCES A MILESTONE ACHIEVEMENT OF THE RESEARCH AND DEVELOPMENT COLLABORATION OF INNOVATIVE CANCER THERAPY
- 2024.1.4
- News Release TAGCyx and Toray Launch Joint Research Initiative to Combat Preeclampsia during Pregnancy as Part of Efforts to Stem Japan’s Declining Birthrate
- 2023.12.12
- News Release TAGCyx has executed a joint research and development agreement with Teika Pharmaceutical
- 2022.9.8
- News Release CAGE Bio and TAGCyx announced execution of a license agreement for development and commercialization of TAGX-0003 for the treatment of immunodermatology diseases mediated by the IFN-γ pathway
- 2022.3.23
- News Release TAGCyx secured a grant funding from ‘Support Program for Orphan drug prior to the Designation’ of Japan Agency for Medical Research and Development (AMED).
- 2021.7.7
- News Release TAGCyx raises approximately 210 million JPY
- 2021.3.22
- News Release Prof. Shinsuke Sando at THE UNIVERSITY OF TOKYO and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE TECHNOLOGICAL IMPROVEMENT OF XENOLIGO®
- 2021.3.5
- News Release TAGCyx announces execution of worldwide exclusive supply of proprietary artificial Ds amidite and patent license agreement with Otsuka Chemical Co., Ltd.
- 2021.2.19
- News Release Prof. Taiichi Sakamoto at CHIBA INSTITUTE TECHNOLOGY and TAGCyx ANNOUNCES THE RESEARCH COLLABORATION of THE STRUCTURAL ANALYSIS OF XENOLIGO®
12